444 related articles for article (PubMed ID: 37511235)
1. Inflammation, Dopaminergic Brain and Bilirubin.
Jayanti S; Dalla Verde C; Tiribelli C; Gazzin S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511235
[TBL] [Abstract][Full Text] [Related]
2. Bilirubin Prevents the TH
Jayanti S; Moretti R; Tiribelli C; Gazzin S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430754
[TBL] [Abstract][Full Text] [Related]
3. Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson's Disease.
De Araújo FM; Frota AF; de Jesus LB; Macedo TC; Cuenca-Bermejo L; Sanchez-Rodrigo C; Ferreira KMS; de Oliveira JVR; de Fatima Dias Costa M; Segura-Aguilar J; Costa SL; Herrero MT; Silva VDA
Cell Mol Neurobiol; 2023 Jan; 43(1):265-281. PubMed ID: 34988761
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
5. Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson's disease models.
Liu W; Gao Y; Chang N
Biochem Biophys Res Commun; 2017 Jan; 482(4):1312-1319. PubMed ID: 27940361
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
[TBL] [Abstract][Full Text] [Related]
7. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
8. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.
Acharya S; Kim KM
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919025
[TBL] [Abstract][Full Text] [Related]
9. Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets.
Yang L; Mao K; Yu H; Chen J
J Neuroimmune Pharmacol; 2020 Dec; 15(4):830-837. PubMed ID: 32529463
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 secreted by human adipose-derived stem cells promotes dopaminergic neuron repair in Parkinson's disease via the inhibition of apoptosis.
Lian C; Huang Q; Zhong X; He Z; Liu B; Zeng H; Xu N; Yang Z; Liao C; Fu Z; Guo H
FASEB J; 2021 Jul; 35(7):e21748. PubMed ID: 34152016
[TBL] [Abstract][Full Text] [Related]
11. Effects of Silibinin Against Prothrombin Kringle-2-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System In Vivo.
Leem E; Oh YS; Shin WH; Jin BK; Jeong JY; Shin M; Kim DW; Jang JH; Kim HJ; Ha CM; Jung UJ; Moon GJ; Kim SR
J Med Food; 2019 Mar; 22(3):277-285. PubMed ID: 30632945
[TBL] [Abstract][Full Text] [Related]
12. A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Sasidharakurup H; Melethadathil N; Nair B; Diwakar S
OMICS; 2017 Aug; 21(8):454-464. PubMed ID: 28816645
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
14. 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
Badillo-Ramírez I; Saniger JM; Rivas-Arancibia S
Neurochem Int; 2019 Oct; 129():104514. PubMed ID: 31369776
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
Tripathy D; Chakraborty J; Mohanakumar KP
Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
[TBL] [Abstract][Full Text] [Related]
16. Neuron-Astrocyte Interactions in Parkinson's Disease.
Miyazaki I; Asanuma M
Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
Mehler-Wex C; Riederer P; Gerlach M
Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
[TBL] [Abstract][Full Text] [Related]
18. Glial Cultures Differentiated from iPSCs of Patients with
Gerasimova T; Stepanenko E; Novosadova L; Arsenyeva E; Shimchenko D; Tarantul V; Grivennikov I; Nenasheva V; Novosadova E
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768317
[TBL] [Abstract][Full Text] [Related]
19. Calpain activation and progression of inflammatory cycles in Parkinson's disease.
Gao A; McCoy HM; Zaman V; Shields DC; Banik NL; Haque A
Front Biosci (Landmark Ed); 2022 Jan; 27(1):20. PubMed ID: 35090325
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Thakur P; Nehru B
Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
